The AD has the worst history of drug candidates’ failures during clinical development. Meager progress has been made in the drug research of AD in the last 15 years. According to Alzheimer’s Association, more than 5.4 million people get affected with the disease in the US which is believed to rise to 16 million by 2050. Here are the ten potential drugs in the late stage of the clinical development for AD in 2018. Total word counts: 1333, Continue reading….